Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT

Inclusion Criteria: 1. Aged 14-65 years, male or female; 2. Participants with CD22 positive B-ALL/LBL who relapsed after allo-HSCT from a related or unrelated donor (regardless of CD22 expression); 3. ECOG physical status score 0\~3, Karnofsky score ≥70; 4. No active grade III/IV graft-versus-host disease (GvHD) or any active liver GvHD, no history of venous occlusive disease (VOD); No active GvHD and no previous history of VOD; 5. Creatinine clearance rate≥50 mL/min (estimate by Cockcroft-Gault Equation); 6. Liver function: alanine transaminase (ALT) and aspartate aminotransferase (AST)≤ 3×upper limit of normal (ULN), and total bilirubin ≤ 2×ULN; 7. Left ventricular ejection fraction (LVEF) ≥50% as measured by echocardiography; 8. Estimated life expectancy \>3 months; 9. Participants voluntarily participate in clinical trial; Understand and know this study, sign an informed consent form, and be willing to follow all experimental procedures. Exclusion Criteria: 1. Allergic or with a history of serious adverse reactions to drugs or drugs with similar chemical structure in this study; 2. Women who are pregnant or breastfeeding, as well as those who are unwilling to take effective contraceptive measures; 3. Severe cardiac dysfunction: left ventricular ejection fraction (LVEF) \<60%; Or severe arrhythmia: a history of a clinically significant corrected interval (QTc) prolongation (male \>450ms; female\>470 ms), ventricular tachycardia, atrial fibrillation, second degree atrioventricular block; myocardial infarction and coronary heart disease with clinical symptoms requiring medical treatment within one year before enrollment; 4. Severe pulmonary disorders (obstructive or restrictive ventilation disorder); 5. Severe liver function impairment: ALT, AST, or TBIL is more than 3 times higher than the upper limit of normal value (ULN); 6. Severe renal impairment: serum Cr is more than 2 times higher than the upper limit of normal (ULN); Or 24-hour urinary creatinine clearance \<50ml/min; 7. Participants with active infection or active bleeding who were deemed intolerance to InO treatment by the investigators; 8. A history of new thrombosis, embolism, cerebral hemorrhage or other diseases within one year before enrollment; 9. Participants suffer from known or other mental disorders that investigators are unable to obtain informed consent and may interfere with their ability to comply with research requirements; 10. A history of major organ surgery within the past six weeks; 11. Drug abuse or chronic alcohol abuse that may affect the study results; 12. Participants with a history of organ transplantation other than HSCT (except BMT); 13. Other situations identified by the investigator as unsuitable to participate in the study.